Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery - Wikidata - awgldk - TriplyDB

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

http://www.wikidata.org/entity/Q28260105

about

The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target Open access chemical probes for epigenetic targets BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Targeting MYC Dependence by Metabolic Inhibitors in Cancer Chemical probes targeting epigenetic proteins: Applications beyond oncology.The cancer theory of pulmonary arterial hypertension.Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival BET Inhibition Attenuates Helicobacter pylori-Induced Inflammatory Response by Suppressing Inflammatory Gene Transcription and Enhancer Activation.Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.Genomic and Epigenomic Alterations in Cancer Bromodomain protein Brd3 promotes Ifnb1 transcription via enhancing IRF3/p300 complex formation and recruitment to Ifnb1 promoter in macrophages Epigenetics in cancer stem cells.Targeting BET bromodomain proteins in solid tumors Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities.Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.Epigenetic interventions for epileptogenesis: A new frontier for curing epilepsy.A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.Unveiling the folding mechanism of the Bromodomains.Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.Epigenetic reprogramming in liver fibrosis and cancer.Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis.A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.Epigenetics in diabetic nephropathy, immunity and metabolism.SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors.Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.

P2860

Q26744292-C598EE92-EB49-4B56-9D81-55FE53C8A712 Q26781872-F2324594-D1EC-4C17-B95F-737356FBCB3F Q27853217-D68BB0D7-8448-48E2-8A29-39C596F8F0C7 Q33591876-5259C54B-58AF-41AB-9C8E-3BD398838B0A Q33608493-A1EC1B2E-914C-4A2B-A6BF-7AAB5595EEB9 Q33751386-F79A4CC9-D248-4BF3-B1E4-601735843FB2 Q33788493-2DD4360F-3A42-4232-84BF-1AC3B3CB9795 Q36185007-D2EB6FB0-4DDE-451B-AB40-1EC00E0D6AB5 Q36341198-0948701D-1E63-454E-814D-A2485E4473D6 Q36906022-D3AF840A-7090-4E28-9EC2-6ED64563BF9A Q36916277-1823674D-ECE8-43D6-8037-B896D1D09AB1 Q37057145-EB88C103-C9EE-4FDC-ABE9-E8C506CBB485 Q37550542-F7036B2F-0961-4E08-B27A-517029FBFF8E Q37618640-41D7176D-7CEF-4A5C-ADCF-B5DB6B52F9CD Q37619860-6CFD38BB-2307-4006-9163-21AD0E5DF924 Q37688355-118DD65E-7067-448F-AC36-E5FA59AEC7A3 Q37718370-F7B7542A-C0F3-4D21-AD2A-9C6D66D86B9B Q37724905-C1F863ED-E652-4589-8C2C-50CECFA4B3D5 Q38260084-3ACC8568-E794-41EA-89D5-CC6880B957BD Q38637914-5F126FAB-22AD-49C5-A466-7D3937EB71B0 Q38668641-21644F51-DE14-4AC8-A186-CC9A07E3692D Q38673660-F06C9A2B-BFB1-416F-830B-3D80F431A17E Q38707876-EC8E0F94-FF8A-4A5E-A130-4C459CF11F37 Q38729732-3C9F39C9-778D-47D7-B5FF-265C4CB12575 Q38730539-65CE7F83-7B37-4DC6-86BB-333FD2282FBE Q38773872-212E60CA-01E3-45A1-96BB-519F9B6061C4 Q38794338-64C1CA96-E5CA-4F9C-BFB9-2A3A4DBBBABB Q38837561-FB0100A4-0A79-4521-8A7E-0D1B50D7D7B8 Q39171785-115306EB-2B1C-4D4A-A906-BC2ECEFFBC38 Q39207675-90C7EABF-913C-4740-951C-6F782C4B66D8 Q39923243-84AC8B11-718D-4D93-B5BA-CA43B301F9E9 Q41682090-B835A680-760F-454F-A36A-C76DB1B5D0FE Q41895213-BAF9ADF3-D141-41EB-B06C-12728D89EB1A Q47157566-9266E662-885C-46F5-AFA3-3E35DA94C5E2 Q47212126-ECBB5F3C-8D38-4366-878E-668699B8AFD1 Q47350877-529FDFD9-9FDB-4B72-9C2A-16EC5203BA67 Q47400790-19217C7E-4FE1-4207-85E4-740272020A7E Q47412518-9A40DC2A-1E4A-4AC8-BEC8-116D1B2CD23D Q47435129-B300A834-3384-40B9-82CC-A864A5E7C112 Q47583420-AB5F74F6-8A00-4D04-9FBC-17DFD80695C0

P2860

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

http://www.wikidata.org/entity/Q28260105

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@ast

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@en

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@nl

type

label

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@ast

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@en

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@nl

prefLabel

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@ast

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@en

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@nl

P1433

Q28260105-2551CC1E-7176-450E-81C1-E7AE493EC4C2

P1476

Q28260105-7DCDC615-2E67-4AFF-8DBC-B7C988D6B88B

P2093

Q28260105-112E0EA0-6B02-494A-9AB4-3F0060EDCA17

Q28260105-1634AD94-6076-4183-BA5E-58A4C467CD3C

Q28260105-5661FD7D-5C4D-4375-93FA-C3DBC26AE9BC

Q28260105-648E61D8-5E86-42A8-8F69-DA2EB02B5A1E

Q28260105-71B2DB6C-6EE5-40B1-B71D-21DDA5BAE14C

Q28260105-A4FA6DC5-D89D-419D-982B-3C8DFEA460C2

Q28260105-B660757E-A490-46C9-B7EF-7E5001379DA4

Q28260105-BB4F299D-54BE-44C3-9C31-3F60BBCBB1F7

P275

Q28260105-897BECEE-BA09-4A9B-A367-D40B8BA94A96

P2860

Q28260105-0027856C-1731-4E60-9E82-3A931BBE9533

Q28260105-00D03314-C460-4938-B511-85291721BD69

Q28260105-0A4E4565-1217-40A7-85EF-516B2A5DCD76

Q28260105-0A5C70CF-2161-4DC2-99E0-85F05367A872

Q28260105-0B9A4FEF-FBBE-4653-9693-8017D3630867

Q28260105-11E6F085-A41A-49B1-9D79-E3F86BD73990

Q28260105-1B1CD35E-0760-4C13-80AA-1B23A69B5AEB

Q28260105-1B7B59D5-A505-4C0F-B141-7731081D0F48

Q28260105-20B30190-B290-40E9-B644-9FD4A187A11F

Q28260105-24A42117-63E6-4361-AEE3-7176940058ED

P304

Q28260105-AC2648C0-6185-4857-B4DF-64510AB7067E

P31

Q28260105-76489C79-6ACC-4959-86E8-C529EF678679

Q28260105-D0F44C92-833B-4AAD-900A-D6A861111243

P3181

Q28260105-F3DEF94A-1A8C-4273-AF91-EFEB243D7D4E

P356

Q28260105-D4FA166E-79C1-4DA7-823D-E1865B7BC576

P407

Q28260105-71F6F53B-9E3D-4676-A8C7-E9E3A986FD05

P433

Q28260105-6F59DF00-B946-4300-8AD6-2084EC56D4B6

P478

Q28260105-15F6CA7D-E214-469D-9C44-FBAC23B4014D

P5008

Q28260105-4415F143-AB16-4F7F-98CA-80F2C9114DDE

P577

Q28260105-ADE34330-AAF5-47FD-9F86-5BB682BAC103

P5875

Q28260105-76D26319-746A-403D-BE13-3EBC5CCEBF19

P698

Q28260105-CC5B6490-7A82-45EF-BA14-FC979A0E9B97

P921

Q28260105-1B413A11-A6FB-481A-85DC-A86463484957

Q28260105-75E17108-9933-41FD-A3CD-6B1ABF3C0036

Q28260105-9DB6294F-1AF0-4997-904C-9F3ABB71827D

Q28260105-FE2C7A13-0556-4A8B-B114-28BBFDB930BD

P932

Q28260105-7211A875-B24D-4BB9-8B53-AF848A10AED8

P3181

P356

ONCOTARGET.3551

P1433

P1476

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

@en

P2093

Bo Liu

http://www.w3.org/2001/XMLSchema#string

Jian Huang

http://www.w3.org/2001/XMLSchema#string

Jing-jing Li

http://www.w3.org/2001/XMLSchema#string

Lei-lei Fu

http://www.w3.org/2001/XMLSchema#string

Liang Ouyang

http://www.w3.org/2001/XMLSchema#string

Mao Tian

http://www.w3.org/2001/XMLSchema#string

Xiang Li

http://www.w3.org/2001/XMLSchema#string

Yonghui Zhang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Structure and ligand of a histone acetyltransferase bromodomain

Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA

Selective inhibition of BET bromodomains

Histone recognition and large-scale structural analysis of the human bromodomain family

Large-scale structural analysis of the classical human protein tyrosine phosphatome

Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation

Regulation of chromatin by histone modifications

The bromodomain: from epigenome reader to druggable target

Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution

Suppression of inflammation by a synthetic histone mimic

P304

5501-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4794579

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.3551

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274643112

http://www.w3.org/2001/XMLSchema#string

P698

25849938

http://www.w3.org/2001/XMLSchema#string

P921

nuclear protein

neoplasm proteins

P932

4467383

http://www.w3.org/2001/XMLSchema#string